News

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Over 20 million patients present to emergency departments (ED) annually with suspected distal extremity trauma, and an estimated 90% to 99% receive X-ray imaging, according to The Journal of Emergency Medicine. However, it is reported that in the lower leg, the incidence of fractures ranges between 8% to 19%, and in the distal arm, the incidence is between 25% to 57%, according to The Journal of Trauma and Acute Care Surgery and The American Journal of Emergency Medicine. A bedside triage device like Accuro XV may significantly reduce the utilization of radiological resources for low-acuity injury triage.

This feasibility study, enrolling 200 participants, aims to acquire fracture images with Accuro XV to evaluate device safety, ability to integrate within ED workflow and the system’s ability to render automated diagnostic ultrasound images.

Accuro XV integrates ultrasound-based bone and 3D soft-tissue imaging technology with AI-enabled software and is designed to enable rapid automated detection and volumetric assessment of skeletal fractures and soft tissue injuries without harmful radiation exposure. Additionally, Accuro XV aims to address limitations in EDs such as identifying soft tissue injuries during the acute phase, ensuring accurate treatment decisions and prompt discharge of those not needing further intervention.

“Since October 2021, we have quickly progressed from design to proof of concept in clinical sites, thanks to our collaboration with BARDA,” said Delphine Le Roux, PhD, PMP, Director of Program Management. “Study data will expedite the development of Accuro XV for comprehensive point-of-care musculoskeletal diagnostics and validate product design with ED physician end-users.”

UVA Health worked with RIVANNA at the study’s inception, providing study start-up and optimization before expanding to The University of Texas Southwestern Medical Center, where faculty treat patients at Parkland Memorial Hospital, one of the nation’s busiest EDs with 240,000 visits annually.

“We are working to transform technological opportunities into applications that may improve treatment for low-acuity patients and reduce wait times,” said Chris Thom, MD, RDMS, Associate Professor of Emergency Medicine at the University of Virginia School of Medicine.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50121C00035. About BARDA.

Learn more here.

Recent News

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals

04/22/2025

ATCC Announces New Executive Leadership Appointments

ATCC, the world’s premier biological materials management and standards organization, today announced several new leadership appointments. Rebecca Bradford, MBA, has been promoted to the role of senior vice president of Government Programs, ATCC Federal Solutions (AFS); Manoj Menon, PhD, has joined the company as chief operating officer; and Rupali Lach was appointed vice president of Commercial Operations.